MELAS syndrome (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes syndrome) is a rare disorder that begins in childhood, usually between two and fifteen years of age, and mostly affects the nervous system and muscles. The most common early symptoms are seizures, recurrent headaches, loss of appetite and recurrent vomiting. Symptoms of MELAS syndrome usually begin between the ages of two and fifteen years, but delayed onset cases have also been reported between fifteen and forty years and late onset cases after forty years. MELAS is caused by mutations in mitochondrial DNA. Some cases of MELAS syndrome appear to occur as the result of a new spontaneous mutation in a mitochondrial gene and are not inherited. It affects males and females in equal numbers.

DelveInsight’s, “MELAS Syndrome Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in MELAS Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Some of MELAS Syndrome Companies are:

• Cyclerion Therapeutics Inc.
• Khondrion BV
• Abliva AB
• And Many Others

 

Request for free Sample Page: https://www.delveinsight.com/sample-request/melas-syndrome-pipeline-insight

 

DelveInsight’s MELAS Syndrome Report covers around 4+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Request for free Sample Page: https://www.delveinsight.com/sample-request/melas-syndrome-pipeline-insight

 

Some of MELAS Syndrome Therapies are:

• CY-6463
• KL133
• KH176
• And Many Others

 

Current MELAS Syndrome Treatment Scenario and MELAS Syndrome Emerging Therapies:

• How many companies are developing MELAS Syndrome drugs?
• How many MELAS Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of MELAS Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the MELAS Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for MELAS Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Page: https://www.delveinsight.com/sample-request/melas-syndrome-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

MELAS Syndrome: Overview

Pipeline Therapeutics

Therapeutic Assessment

MELAS Syndrome – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

MELAS Syndrome Collaboration Deals

Late Stage Products (Phase III)

Drug Name: Company Name

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

CY-6463: Cyclerion Therapeutics, Inc.

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

KL133: Abliva AB

Drug profiles in the detailed report…..

Inactive Products

MELAS Syndrome Key Companies

MELAS Syndrome Key Products

MELAS Syndrome- Unmet Needs

MELAS Syndrome- Market Drivers and Barriers

MELAS Syndrome- Future Perspectives and Conclusion

MELAS Syndrome Analyst Views

MELAS Syndrome Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/melas-syndrome-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/melas-syndrome-pipeline-insight